ライフサイエンスコーパス: drug-resistant

1 mors, including those that are classified as drug resistant.

2 hylococcus aureus, are becoming increasingly drug-resistant.

3 haracterized to determine the percentages of drug-resistant ALDH+ cells, MDR-1/ABCG2 overexpressing c

4 examine dose-dependent cytotoxic effects on drug-resistant and drug-sensitive cancer cell lines.

5 profiling and functional characterization of drug-resistant and engineered cell lines.

6 n 2000 experimentally supported circulating, drug-resistant and prognosis-related lncRNA biomarkers;

7 His cytomegalovirus was multi-drug resistant, and was treated with maribarir, intravit

8 ociated with brain malformations, tend to be drug-resistant, and have been linked to an increased ris

9 Pancreatic cancer is usually advanced and drug resistant at diagnosis.

10 antibiotics for combination therapy against drug resistant bacteria can be realized on an integrated

11 e a prototype for point-of-care diagnosis of drug resistant bacteria with visual signal output.

12 on macrophage function and killing of multi-drug resistant bacteria.

13 ntial new class of antibiotics against multi-drug resistant bacteria.

14 antimicrobials are urgently needed to combat drug-resistant bacteria and to overcome the inherent dif

15 Surveillance of drug-resistant bacteria is essential for healthcare prov

16 iotics against two clinically isolated multi-drug-resistant bacteria strains (including carbapenem-re

17 against multidrug-resistant and extensively drug-resistant bacteria, including ESBL, carbapenem- and

18 shown in-vivo and in-vitro efficacy against drug-resistant bacteria.

19 ing approach for detection of live, dead and drug-resistant bacteria.

20 a purulent animal wound model infected with drug-resistant bacteria.

21 reat severe infections caused by extensively drug-resistant bacteria.

22 biotic of last resort used in treating multi-drug resistant bacterial infections in humans.

23 biotic use has led to increased isolation of drug resistant bacterial strains from respiratory sample

24 re urgently needed because the rapid rise in drug-resistant bacterial infections in recent decades ha

25 bacteriophages (phages) for the treatment of drug-resistant bacterial infections is one approach that

26 rtant combination therapies for treatment of drug-resistant bacterial infections.

27 ion, which is essential for the treatment of drug-resistant bacterial infections.

28 ead to novel approaches for the treatment of drug-resistant bacterial infections.

29 More and more multi-drug-resistant bacterial strains cause life-threatening

30 The emergence of multi-drug-resistant bacterial strains further complicates pat

31 l-acquired infections (HAIs) attributed to a drug-resistant bacterium in the United States, and resis

32 e therapy for individuals with CF and highly drug-resistant Bcc and B. gladioli infections.

33 sine kinase inhibitors (TKIs) may select for drug-resistant BCR-ABL1 kinase domain (KD) mutants.

34 s partially explained by microbes adopting a drug-resistant biofilm mode of growth during infection.

35 ll molecules for antifungal activity against drug-resistant C. albicans.

36 mors established from drug-sensitive but not drug-resistant cancer cell lines.

37 present work thus reveals a chemotherapeutic drug-resistant cancer cell vulnerability in PERK and sug

38 hat following initial response to treatment, drug-resistant cancer cells frequently evolve and, event

39 erapy less effective due to proliferation of drug-resistant cancer cells when using very long inducti

40 carcinogenesis and offer a novel approach to drug-resistant cancer therapy.

41 to serve as tumor killers for late-stage or drug-resistant cancers.

42 ncer therapy, specifically in the context of drug-resistant cancers.

43 t only demonstrated the competing effects of drug-resistant cell expansion versus overall tumor regre

44 bclones could be comprised of metastatic and drug resistant cells.

45 rug-sensitive cells increasing but growth of drug-resistant cells decreasing effective drug inhibitio

46 ional chemotherapy has not been effective as drug-resistant cells escape lethal DNA damage effects by

47 its restored expression impaired survival of drug-resistant cells, sensitized them to TKIs in vitro,

48 and -time course experiments showed that the drug-resistant cells, which express lower expression and

49 cancer and particularly in chemotherapeutic drug-resistant cells.

50 The alarming rise in drug-resistant clinical cases of tuberculosis (TB) has n

51 acious antimalarials to address the emerging drug-resistant clinical cases.

52 ssible driver of myeloma cell evolution in a drug-resistant clone.

53 atment failure resulting from persistence of drug-resistant clones after conventional chemotherapy tr

54 persister" tumor cells underlie emergence of drug-resistant clones and contribute to relapse and dise

55 ctivity, but after initial therapy response, drug-resistant clones restore myosin II activity to incr

56 mivudine at Met184Val, and when at least one drug-resistant codon was detected in a participant's pre

57 loxacin heteroresistance and the presence of drug resistant colony forming units (CFUs) at 1 per 1000

58 The liver metastasis showed drug-resistant CSC- and EMT-like phenotype with aerobic

59 ssays and expanded clones with wild-type and drug-resistant defective proviruses.

60 Drug-resistant dormant myeloma cells that reside in spec

61 Most clonal groups were highly drug resistant due to the presence of multiple antimicro

62 tous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanom

63 a potential therapeutic strategy to overcome drug-resistant EGFR mutations that emerge within the ATP

64 ients who underwent total callosotomy due to drug-resistant epilepsy (CPs; two females), in three non

65 eizures (odds ratio [OR] = 0.21, p = 0.032), drug-resistant epilepsy (OR = 0.23, p = 0.022), and infa

66 ve stimulation (VNS) is widely used to treat drug-resistant epilepsy and depression.

67 xtensively used to find the seizure focus in drug-resistant epilepsy and is of growing importance in

68 n a retrospective cohort of 28 patients with drug-resistant epilepsy implanted with intracranial elec

69 be epilepsy (TLE) is the most common type of drug-resistant epilepsy in adults, with an unknown etiol

70 Sleep fragmentation in focal drug-resistant epilepsy is associated with ictal and int

71 Patients with drug-resistant epilepsy often require surgery to become

72 wall and in neocortical parenchyma of young, drug-resistant epilepsy patients (18-28 years old) who u

73 s placed on the cortex, is typically used in drug-resistant epilepsy patients, and is increasingly be

74 electroencephalographic (SEEG) recordings in drug-resistant epilepsy patients, to qualitatively and q

75 d epileptic bursts in 36 patients with focal drug-resistant epilepsy who underwent combined stereo-el

76 previously collected from 123 patients with drug-resistant epilepsy who underwent resective epilepsy

77 tual resection predicts surgical outcome for drug-resistant epilepsy' by Kini et al. (doi:10.1093/bra

78 as these individuals can experience lifelong drug-resistant epilepsy, cerebral palsy, feeding difficu

79 al lobe epilepsy represents a major cause of drug-resistant epilepsy.

80 , we measured the "escape time" required for drug-resistant Escherichia coli populations to eclipse a

81 induce therapeutic hypothermia for treating drug-resistant fever, and for improving glucose and ener

82 anted device in adults (age >=18 years) with drug-resistant focal epilepsy followed at 35 centres acr

83 Drug-resistant focal epilepsy is a large-scale brain net

84 of the presurgical evaluation, patients with drug-resistant focal epilepsy were instructed to overtly

85 In kainic-acid-induced mouse models of drug-resistant focal epilepsy, electric-field changes in

86 For patients with drug-resistant focal epilepsy, excision of the epileptog

87 ry is a widely accepted treatment option for drug-resistant focal epilepsy.

88 seizures from nine patients with unilateral drug-resistant focal epilepsy.

89 Temporal lobe epilepsy is the most common drug-resistant form of epilepsy in adults.

90 Patients with highly drug-resistant forms of tuberculosis have limited treatm

91 in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated to

92 tro and mouse-model efficacy toward multiple-drug-resistant fungal pathogens, exhibits a wide safety

93 Global outbreaks of drug-resistant fungi such as Candida auris are thought t

94 ed to counter the escalating threat posed by drug-resistant fungi.

95 a wide range of KIT mutants in patients with drug-resistant GISTs.

96 identification and detection of new forms of drug-resistant gonorrhoea.

97 ug target against the rising threat of multi-drug-resistant Gram-negative bacteria.

98 or novel antibiotics is especially acute for drug-resistant Gram-negative pathogens(1,2).

99 perties make it a key agent for treatment of drug-resistant Gram-positive infections.

100 is characterized by colonization with multi-drug-resistant healthcare-associated pathogens.

101 Drug resistant HIV variants, including minority variants

102 that RPV LA will not inhibit transmission of drug-resistant HIV-1 and may select for drug-resistant v

103 The presence of high-abundance drug-resistant HIV-1 jeopardizes success of antiretrovir

104 ations, the clinical impact of low-abundance drug-resistant HIV-1 variants (LA-DRVs) at levels <15%-2

105 Candida auris is an emerging multi-drug-resistant human fungal pathogen.

106 TAMs to not only eradicate highly aggressive drug-resistant human lung and pancreas cancers in mice,

107 stantial percentage of patients suffer from "drug-resistant" hypertension, a condition associated wit

108 Drug resistant infections represent one of the most chal

109 Highly drug-resistant infections are disproportionally caused b

110 d, ten million people will die annually from drug-resistant infections by 2050.

111 Current studies suggest that human drug-resistant infections can be either environmentally

112 nisms of action that are capable of treating drug-resistant infections(1).

113 biotic resistance in the treatment of severe drug-resistant infections.

114 ears could reduce disease burden and prevent drug-resistant infections.

115 unds showed better activity profiles against drug-resistant influenza A strains, as well as influenza

116 gal indicator strains, notably against multi-drug resistant Klebsiella pneumoniae ATCC 700603 while i

117 shortening regimens for drug-susceptible and drug-resistant latent and active M. tuberculosis infecti

118 or ALL in general and may suppress incurable drug-resistant leukemia forms.

119 c GSK3alpha inhibition profoundly sensitized drug-resistant leukemias to asparaginase.

120 Drug resistant M. tuberculosis is an emerging threat for

121 Combating drug-resistant malaria urgently requires the development

122 ologies in reporting the clinically relevant drug-resistant markers, including full gene deletions.

123 rates of AMR with 51.9% (28/54) being multi-drug resistant (MDR) and 53.6% of these (15/28) being ex

124 15% of isolates multi-drug resistant (MDR) to first-line antibiotics and 60% w

125 found that PDAC consists of ALDH+/CD133+ and drug-resistant (MDR1+) subtypes of CSCs with specific me

126 Moreover, our analysis revealed a drug-resistant mechanism through which overexpression of

127 y patients and help to better understand the drug-resistant mechanism to TKIs.

128 genetic analysis is important to understand drug-resistant mechanisms; however, the clinical signifi

129 ,10-phenanthroline-5,6-dione [phendione]) in drug-resistant melanoma.

130 of prostate phenotypes from normal tissue to drug-resistant metastases.

131 ved outcomes for breast cancer patients with drug-resistant metastatic disease.

132 The drug-resistant metastatic state was dependent on histone

133 have investigated the clinical relevance of drug resistant minority variants, but the level at which

134 proved chemotherapeutic response in a highly drug-resistant mouse model of NSCLC.

135 ed metabolic reprogramming in the context of drug-resistant Mtb infection, previous literature examin

136 gy and differences in the immune response to drug-resistant Mtb provides significant insights into ho

137 e drug-susceptible (MIC = 0.0039 mug/mL) and drug-resistant Mtb strains (MIC = 0.0078 mug/mL).

138 eral independent acquisitions of extensively drug-resistant/multidrug-resistant-inducing plasmids, pr

139 atment is initiated, cancers already contain drug-resistant mutant cells.

140 Drug-resistant mutant kinases are valuable tools in drug

141 replication inhibitors, but the emergence of drug-resistant mutants is observed frequently, highlight

142 a paradigm, we have developed kinase-active, drug-resistant mutants of ERK5.

143 pandemics by reassortment and generation of drug-resistant mutants, which render antivirals and curr

144 This led to the identification of the novel drug-resistant mutation L46P located outside the drug-bi

145 Phylogenetic and network inferences, drug resistant mutations (DRMs), subtypes and HIV-1 dive

146 Most drug-resistant mutations are located near the ethambutol

147 Drug-resistant mutations cluster near loops that lay on

148 <400 copies per mL), and none had multiclass drug-resistant mutations detected.

149 within expanded clones, including those with drug-resistant mutations.

150 ral load, CD4 cell count, and antiretroviral drug-resistant mutations.

151 Drug-resistant mycobacteria are a rising problem worldwi

152 ree-phage cocktail to treat a patient with a drug-resistant Mycobacterium abscessus suggests that pha

153 Automated genotyping of drug-resistant Mycobacterium tuberculosis (MTB) directly

154 health concern and the growing prevalence of drug-resistant Mycobacterium tuberculosis is making dise

155 H-MYCN mice; (ii) orthotopic xenografts of a drug-resistant NB line SK-N-BE(2)C (mutated TP53); (iii)

156 (mutated TP53); (iii) flank xenografts of a drug-resistant NB-PDX; and (iv) xenografts of Ewing sarc

157 The conservation of hypoxic drug-resistant niches in bacterial and fungal biofilms i

158 -LC-07-48 which exhibited greater potency in drug-resistant NSCLC cells (IC(50) = 17 nM) and in mice

159 vated c-Myc-miR-137-EZH2 pathway in platinum drug-resistant or recurrent ovarian cancer patients.

160 We discuss novel therapeutic options for drug-resistant or refractory CMV infection, including ma

161 Implementing an extensively drug-resistant organism registry reduced CRE spread, eve

162 tibiotic prescribing can contribute to multi-drug resistant organisms (MDRO) and Clostridioides diffi

163 ted effect of ASP on rates of infection with drug-resistant organisms.

164 iveness to reduce infections of high-profile drug-resistant organisms.

165 is review, we have outlined the evidence for drug-resistant Orientia tsutsugamushi, assessed the evid

166 also markedly extended survival of mice with drug-resistant, orthotopic NB and it caused long-term (6

167 actam over polymyxins or aminoglycosides for drug-resistant P. aeruginosa infections.

168 ycoside-based regimens for infections due to drug-resistant P. aeruginosa.

169 Prevalence of drug-resistant P. falciparum highlights the need to unde

170 of PfCRT, explaining the impaired fitness of drug-resistant parasites.

171 Mycobacterium abscessus is an extensively drug-resistant pathogen that causes pulmonary disease, p

172 Acinetobacter baumannii is a feared, drug-resistant pathogen, characterized by its ability to

173 both aminoglycoside-producing and clinically drug-resistant pathogenic bacteria.

174 ons (HAI) resulting from the transmission of drug-resistant pathogens affect hundreds of millions of

175 As drug-resistant pathogens erode the effectiveness of the

176 klace 1 against both standard and clinically drug-resistant pathogens implies that the presence of Cu

177 nd can inform efforts to limit the spread of drug-resistant pathogens in hospitals.

178 the group of three "critical priority" multi-drug-resistant pathogens listed by WHO and is responsibl

179 his paves the way for selective targeting of drug-resistant pathogens without disrupting or selecting

180 itical to combating the growing emergence of drug-resistant pathogens.

181 of the misuse of antibiotics and the rise in drug-resistant pathogens.

182 ignificance of horine and verine in fighting drug-resistant pathogens.

183 ost extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-negative pathogens.

184 the tumor develops into a more invasive and drug-resistant phenotype and ultimately recurs.

185 wn kinase network topologies associated with drug-resistant phenotypes or specific genetic mutations.

186 The emergence and spread of drug-resistant Plasmodium falciparum impedes global effo

187 ual blood stages of both sensitive and multi-drug-resistant Plasmodium falciparum strains.

188 ol-2-yl)ethyl sulfide (BPTES) selected for a drug-resistant population with increased endogenous GLS2

189 c-Myc in several lung cancer cell lines and drug-resistant primary lung cancer cells.

190 ere also used to quickly identify the highly drug-resistant profile of these outbreak-associated C. j

191 beta) signals to TICs, inducing invasive and drug-resistant properties and further upregulating IL-33

192 n-Darby canine kidney transfected with multi-drug resistant protein 1 (MDCK-MDR1), and human U251 GBM

193 e formulations for the treatment of multiple-drug-resistant pulmonary infections is gaining attention

194 olic pathways, with particular relevance for drug resistant, relapsed FL.

195 e initially restricted to clinical settings, drug resistant S. aureus is now one of the key causative

196 ng the last 3 years with large proportion of drug resistant S. Typhi cases.

197 s have a limited duration of activity due to drug-resistant secondary KIT mutations that arise (or th

198 Drug-resistant seizures are common in patients with leuc

199 Affected individuals exhibit early onset drug-resistant seizures, developmental delay, and cognit

200 Notably, the emergence of additional drug-resistant species, such as Candida auris and Candid

201 Susceptible and drug resistant Staphylococcus aureus strains were deposi

202 Multi-drug resistant Staphylococcus aureus, including methicil

203 s (SAGN) cases increased owing to a surge in drug-resistant Staphylococcus aureus infections, both in

204 d stabilizes the ribosome in an inactive and drug-resistant state.

205 , methicillin-resistant S. aureus (MRSA; the drug resistant strain) is able to grow on gel modified e

206 lving 14 patients infected by an extensively drug-resistant strain of Pseudomonas aeruginosa was dete

207 eric pathogens, including recalcitrant multi-drug resistant strains.

208 ough the mechanisms remain poorly clarified, drug-resistant strains are widely believed to be less in

209 causes of death worldwide, and the number of drug-resistant strains is increasing.

210 t Mtb provides significant insights into how drug-resistant strains of Mtb differentially impact immu

211 Recent evidence has shown that certain drug-resistant strains of Mtb modulate host metabolic re

212 new antibiotics, particularly because multi-drug-resistant strains of this bacterium cause serious n

213 lated to introduction of relatively virulent drug-resistant strains or movements of vulnerable popula

214 clinical presentation, the growing spread of drug-resistant strains, and policy and economic ramifica

215 ve bacteria, anaerobes, atypicals, and other drug-resistant strains, like methicillin-resistant Staph

216 In particular, for drug-resistant strains, limited medication is available.

217 blood- stage Plasmodium parasites, including drug-resistant strains.

218 tive interactions between drug-sensitive and drug-resistant subclones.

219 antibiotic efficacy when communities include drug-resistant subpopulations, leading to a wide range o

220 In the face of the global threat from drug-resistant superbugs, there remains an unmet need fo

221 ntralizing this important test for combating drug-resistant superbugs.

222 bal spread of beta-lactamase-producing multi-drug-resistant "superbugs" has caused increased alarm wi

223 rifampicin (RIF), pyrazinamide (PZA)], multi-drug resistant TB (MDR-TB) and pan-susceptible TB (PANS-

224 olates, we report the geospatial patterns of drug resistant TB, particularly the dispersion of Lisboa

225 smission in settings with high incidences of drug-resistant TB are poorly understood.

226 in ensuring that all persons diagnosed with drug-resistant TB are started on an appropriate treatmen

227 tuberculosis sequencing data on extensively drug-resistant TB cases in KwaZulu-Natal, South Africa,

228 ) and dynamic changes, and characterized the drug-resistant TB clustering risk using routine microbio

229 ding infectious cause of death globally, and drug-resistant TB strains pose a serious threat to contr

230 found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive.

231 ized that lower proportions of patients with drug-resistant TB would have culturable Mycobacterium tu

232 f HIV coinfection, high preexisting rates of drug-resistant TB, human migration, and pathoadaptive ev

233 n more effective therapeutics against TB and drug-resistant TB.

234 ypothesized that the cognitive impairment in drug-resistant temporal lobe epilepsy could be due to pe

235 the hippocampus and temporal lobe cortex of drug-resistant temporal lobe epilepsy patients who under

236 se may contribute to cognitive impairment in drug-resistant temporal lobe epilepsy.

237 etic resonance images from 121 patients with drug-resistant TLE across 3 independent epilepsy centers

238 the prevalence of the MDR-TB and extensively drug resistant tuberculosis (XDR-TB) cases, there is an

239 (DLM) in treatment regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeu

240 In generalized drug-resistant tuberculosis (DR-TB) HIV epidemics, ident

241 Individuals treated for drug-resistant tuberculosis (DR-TB) with aminoglycosides

242 eat individuals presumed to be infected with drug-resistant tuberculosis (DR-TB).

243 ent sputum samples for clinical diagnosis of drug-resistant tuberculosis (DR-TB).

244 s new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB).

245 Multi-drug-resistant tuberculosis (MDR-TB) is simultaneously r

246 r AMR pathogens, both historical and ongoing drug-resistant tuberculosis (TB) epidemics are character

247 Patterns of transmission of drug-resistant tuberculosis (TB) remain poorly understoo

248 A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail glo

249 Drug-resistant tuberculosis (TB), one of the leading cau

250 Patients with extensively drug-resistant tuberculosis (XDR-TB) are also resistant

251 the most recent years, notification rates of drug-resistant tuberculosis among new tuberculosis cases

252 on for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-

253 Several key new developments regarding drug-resistant tuberculosis are outlined in this Commiss

254 ve led WHO to recommend all-oral therapy for drug-resistant tuberculosis for the first time ever in 2

255 The recent rise of drug-resistant tuberculosis has complicated the choice o

256 iline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be compromised by

257 Drug-resistant tuberculosis is a major public health con

258 ome (cure, dropout, death, or development of drug-resistant tuberculosis or treatment failure) was re

259 Drug-resistant tuberculosis persists as a major public h

260 Drug-resistant tuberculosis represents a global emergenc

261 Notification rates of drug-resistant tuberculosis showed diverse trends, with

262 ant tuberculosis and over 90% of extensively drug-resistant tuberculosis strains are also PZA resista

263 treatment, the patient developed extensively drug-resistant tuberculosis, highlighting the importance

264 Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved surviva

265 lamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed inte

266 specifically to isoniazid, leading to multi-drug-resistant tuberculosis.

267 d not on ART, and 1749 (15%) had extensively drug-resistant tuberculosis.

268 gence of multidrug-resistant and extensively drug-resistant tuberculosis.

269 ens) has demonstrated activity against multi-drug-resistant tuberculosis.

270 HIV patients with multidrug and extensively drug-resistant tuberculosis.

271 e of the size and dynamics of a preexisting, drug-resistant tumor cell population versus a slow-growi

272 d suggest a mechanism for the development of drug-resistant tumors and a target for overcoming resist

273 ERD), which degrades the ERalpha receptor in drug-resistant tumors and has been approved for the trea

274 st various malignant solid tumors, including drug-resistant tumors and metastatic tumors.

275 antiapoptotic protein often overexpressed in drug-resistant tumors, as a cis-DDP-binding protein.

276 The recent rise of extensively drug-resistant typhoid bears the biosocial footprint of

277 d conjugate vaccine rollouts and extensively drug-resistant typhoid.

278 ors that are broadly effective against known drug-resistant variants are needed, although such compou

279 d by seven major bacterial species and their drug-resistant variants in a network of 357 hospital war

280 Viremia, emergence of drug-resistant variants, and quasispecies diversificatio

281 efficacy is compromised by the emergence of drug-resistant variants.

282 retains efficacy against a broad spectrum of drug-resistant variants.

283 The emergence of drug-resistant viral strains and uncertain vaccine prosp

284 mal treatment adherence and the emergence of drug-resistant viral variants, thereby limiting future t

285 n of drug-resistant HIV-1 and may select for drug-resistant virus.

286 of available compounds and the emergence of drug-resistant viruses.

287 Infections with MDR and extensively drug resistant (XDR) E. coli, XDR K. pneumoniae, and MDR

288 itive for S. Typhi, and all were extensively drug resistant (XDR) S. Typhi.

289 reported multidrug resistant and extensively drug resistant (XDR) TB cases, driven predominantly by t

290 atG was associated with baseline extensively drug resistant (XDR) TB, increased acquired fluoroquinol

291 and 53.6% of these (15/28) being extensively drug resistant (XDR).

292 the new agents against the most extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-n

293 istory of a successful strain of extensively drug-resistant (XDR) TB known as LAM4/KZN, first identif

294 tment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis.

295 of multidrug-resistant (MDR) and extensively drug-resistant (XDR) V. cholerae to identify AMR genes a

296 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB.

297 50%) had MDR, 4/14 (29%) had pre-extensively-drug-resistant (XDR), and 3/14 (21%) had XDR.

298 st-line antibiotics and 60% were extensively drug-resistant (XDR), resistant to first-line antibiotic

299 and 53.6% of these (15/28) being extensively drug-resistant (XDR).

300 Candida auris is an emerging multi-drug resistant yeast that causes systemic infections.